The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Gynaecological cancers and malignant gliomas showed moderate to strong nuclear positivity. Remaining malignancies were weakly stained or negative.
A majority of malignant tissues were negative. Some ovarian-, cervical- and endometrial cancers showed moderate nuclear immunoreactivity.
Most malignant gliomas, ovarian and cervical cancers as well as several endometrial, thyroid and urothelial cancers showed moderate to strong nuclear immunoreactivity. Remaining malignant tissues were mostly negative.
Validation
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
The multi-targeting antibody yielding a staining pattern consistent with gene/protein characterization data for all of the genes
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
